Commentaries

Mycoplasma and cancer: in search of the link

https://doi.org/10.18632/oncotarget.264 Melissa B. Rogers

271-273

PDF  |  HTML  |  How to cite

Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs

https://doi.org/10.18632/oncotarget.265 Ingeborg M.M. van Leeuwen,  and Sonia Laín

274-276

PDF  |  HTML  |  How to cite

A stressful life (or death): Combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability

https://doi.org/10.18632/oncotarget.266 Paul Workman,  and Faith E. Davies

277-280

PDF  |  HTML  |  How to cite

The “Infectious” Nature of Human Prostate Cancer: A Cautionary Note

https://doi.org/10.18632/oncotarget.267 Karen S. Sfanos,  and John T. Isaacs

281-283

PDF  |  HTML  |  How to cite

Enhancing proteotoxic stress as an anticancer strategy

https://doi.org/10.18632/oncotarget.268 Steven Grant

284-286

PDF  |  HTML  |  How to cite

Detecting and monitoring lymphoma with high-throughput sequencing

https://doi.org/10.18632/oncotarget.270 Harlan Robins

287-288

PDF  |  HTML  |  How to cite

Research Papers

Association of Mycoplasma hominis infection with prostate cancer

https://doi.org/10.18632/oncotarget.256 Yulia A. Barykova, Denis Yu. Logunov, Maxim M. Shmarov, Andrei Z. Vinarov, Dmitry N. Fiev, Natalia A. Vinarova, Irina V. Rakovskaya, Patricia Stanhope Baker, Inna Shyshynova, Andrew J. Stephenson, Eric A. Klein, Boris S. Naroditsky, Alexander L. Gintsburg,  and Andrei V. Gudkov

289-297

Abstract  |  PDF  |  HTML  |  How to cite

Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting

https://doi.org/10.18632/oncotarget.261 Aman P. Mann, Rohan C. Bhavane, Anoma Somasunderam, Brenda Liz Montalvo-Ortiz, Ketan B. Ghaghada, David Volk, René Nieves-Alicea, K. Stephen Suh, Mauro Ferrari, Ananth Annapragada, David G. Gorenstein,  and Takemi Tanaka

298-304

Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite

Research Perspectives

Caveolin-1 in sarcomas: friend or foe?

https://doi.org/10.18632/oncotarget.255 Miguel Sáinz-Jaspeado, Juan Martin-Liberal, Laura Lagares-Tena, Silvia Mateo-Lozano, Xavier Garcia del Muro,  and Oscar M. Tirado

305-312

Abstract  |  PDF  |  HTML  |  How to cite

The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth

https://doi.org/10.18632/oncotarget.259 Patrick Schmidt,  and Hinrich Abken

313-320

Abstract  |  PDF  |  HTML  |  How to cite

INPP4B: the New Kid on the PI3K Block

https://doi.org/10.18632/oncotarget.260 Irina U. Agoulnik, Myles C. Hodgson, Wayne A. Bowden,  and Michael M. Ittmann

321-328

Abstract  |  PDF  |  HTML  |  How to cite

Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma

https://doi.org/10.18632/oncotarget.263 John M. Koomen,  and Keiran S. M. Smalley

329-335

Abstract  |  PDF  |  HTML  |  How to cite

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

https://doi.org/10.18632/oncotarget.262 Ryan B. Corcoran, Jeffrey Settleman,  and Jeffrey A. Engelman

336-346

Abstract  |  PDF  |  HTML  |  How to cite

Mitochondrial Compartmentalized Protein Folding and Tumor Cell Survival

https://doi.org/10.18632/oncotarget.273 Dario C. Altieri

347-351

Abstract  |  PDF  |  HTML  |  How to cite

Copyright © 2025 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC